Weight-loss and progesterone treatments for early uterine lining disease
Treatments studied
Part of Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial studies a weight-management approach plus a progesterone-releasing IUD (LNG-IUS) and megestrol to treat endometrial atypical hyperplasia, a high-risk precancer of the uterine lining. It may help shrink or control the abnormal cells while supporting fertility or keeping the uterus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 45
- Your body mass index (BMI) is 24 or higher
- A biopsy or procedure confirms endometrial atypical hyperplasia (uterine lining precancer) from pathology
- You strongly want fertility preservation or strongly want to keep your uterus
- You can reliably follow up on time at Obstetrics and Gynecology Hospital of Fudan University
- You do not have major uncontrolled organ problems (for example, significant liver or kidney dysfunction)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding GnRH medicine and letrozole to standard progestin treatment can better control early, low-risk endometrial cancer or atypical hyperplasia in people who are not obese. It may help some patients avoid progression while keeping the uterus, especially for those wanting future fertility.
This trial tests a combination of two hormone-blocking drugs (GnRHa plus letrozole) for women with early-stage, obesity-related endometrial cancer who haven't responded well to standard hormone therapy alone. The goal is to preserve the uterus and fertility while controlling the cancer.
This study looks at whether a hormone-releasing IUD (LNG-IUS) can treat early-stage endometrial cancer or very early abnormal cell growth while helping you keep the option for future pregnancy. It aims to see how well the treatment works and how it affects fertility-related outcomes.
This trial tests combining a weight-loss medication (mazdutide) with a hormone-releasing intrauterine device (LNG-IUS) to treat early-stage uterine cancer or precancerous changes while preserving fertility. It aims to help patients who are overweight or obese and wish to avoid hysterectomy.
This study tests whether a three-month program that includes weight-loss medications and hormone therapy before surgery is better than surgery alone for women with early-stage endometrial cancer and severe obesity. The goal is to see if this approach improves surgical outcomes and overall health.
This trial tests whether medroxyprogesterone acetate (a progesterone hormone) plus atorvastatin (a cholesterol medicine) can treat early, limited problems in the womb lining—either atypical hyperplasia or early cancer (Grade 1) that has not spread into the muscle wall. It may help shrink or clear the abnormal tissue while supporting keeping fertility and the uterus.
Hear when a new Atypical Endometrial Hyperplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.